netFormulary
 Report : Medicines with links to NICE 26/11/2020 06:06:41

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Panobinostat 08.01.05 Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Abatacept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abciximab 02.09 Formulary NICE TA47: Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
Abiraterone 08.03.04.02 Formulary NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Abiraterone 08.03.04.02 Formulary NICE TA259: Abiraterone for castration resistant prostate cancer
Adalimumab 13.05.03 Formulary NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adalimumab 13.05.03 Formulary NICE TA146: Psoriasis - adalimumab
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Adalimumab 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Adalimumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Formulary NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Adalimumab 10.01.03 Formulary NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adefovir Dipivoxil 05.03.03.01 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Adefovir Dipivoxil 05.03.03.01 Formulary NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Afatinib 08.01.05 Formulary NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
Aflibercept 11.08.02 Formulary NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA294: Macular degeneration (wet age-related) - aflibercept
Aflibercept 11.08.02 Formulary NICE TA346: Aflibercept for treating diabetic macular oedema
Aflibercept 11.08.02 Formulary NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 08.01.05 Non Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Alemtuzumab 08.02.03 Formulary NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
Alirocumab 02.12 Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177: Eczema (chronic) - alitretinoin
Alteplase 02.10.02 Formulary NICE TA264: Alteplase for treating acute ischaemic stroke
Alteplase 02.10.02 Non Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Amantadine 05.03.04 Formulary NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA245: Venous thromboembolism - apixaban (hip and knee surgery
Apixaban 02.08.02 Formulary NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apixaban 02.08.02 Formulary NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban
Apremilast 13.05.03 Formulary NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Apremilast 13.05.03 Formulary NICE TA433: Apremilast for treating active psoriatic arthritis
Aripiprazole 04.02.01 Formulary NICE TA292: Bipolar disorder (children) - aripiprazole
Aripiprazole 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Axitinib 08.01.05 Formulary NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Azacitidine 08.01.03 Formulary NICE TA218: azacitidine for myelodysplastic syndromes
Belimumab 10.01.03 Formulary NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for CLL
Bevacizumab 08.01.05 Formulary NICE TA263: Breast cancer with capecitabine
Bevacizumab 08.01.05 Formulary NICE TA212: Colorectal cancer (metastatic) - bevacizumab
Bevacizumab 08.01.05 Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Bevacizumab 08.01.05 Formulary NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab 08.01.05 Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bivalirudin 02.08.01 Non Formulary NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
Bivalirudin 02.08.01 Non Formulary NICE CG94: Unstable angina and NSTEMI
Boceprevir 05.03.03.02 Formulary NICE TA253: Boceprevir for the treatment of genotype 1 chronic hepatitis C
Bortezomib 08.01.05 Formulary NICE TA129: Multiple myeloma - bortezomib
Bortezomib 08.01.05 Formulary NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA311: Multiple myeloma - bortezomib (induction therapy
Bortezomib 08.01.05 Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bosutinib 08.01.05 Formulary NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Botulinum Toxin Type A 04.07.04.02 Non Formulary NICE TA260: Botox for migraine prophylaxis
Botulinum Toxin Type A 04.09.03 Formulary NICE TA260 : Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Botulinum Toxin Type A 04.09.03 Formulary NICE TA260 : Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Cabazitaxel 08.01.05 Formulary NICE TA255: Cabazitaxel for prostate cancer
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Capecitabine 08.01.03 Formulary NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
Capecitabine 08.01.03 Formulary NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer
Capecitabine 08.01.03 Formulary NICE TA191: Capecitabine for the treatment of advanced gastric cancer
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Ceritinib 08.01.05 Formulary NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Certolizumab Pegol 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab Pegol 10.01.03 Formulary NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 10.01.03 Formulary NICE TA186: Certolizumab pegol for the treatment of rheumatoid arthritis
Cetuximab 08.01.05 Formulary NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab 08.01.05 Formulary NICE TA145: Head and neck cancer - cetuximab
Cetuximab 08.01.05 Formulary NICE TA242: TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Cetuximab 08.01.05 Formulary NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Cetuximab 08.01.05 Formulary NICE TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab
Cetuximab 08.01.05 Formulary NICE TA176: Colorectal cancer (first line) - cetuximab
Ciclosporin 11.08 Formulary NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Clopidogrel 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Clopidogrel 02.09 Formulary NICE TA80: Acute coronary syndromes - clopidogrel
Colistimethate inhaler 05.01.07 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Crizotinib 08.01.05 Formulary NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Cubitan A2.03.02 Non Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Dabigatran 02.08.02 Formulary NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dabigatran 02.08.02 Formulary NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabrafenib 08.01.05 Formulary NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Daclatasvir 05.03.03.02 Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02.04 Formulary NICE TA441: Daclizumab for treating relapsing–remitting multiple sclerosis
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Darbepoetin Alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Dasabuvir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Dasatinib 08.01.05 Formulary NICE TA241: CML for whom treatment with imatinib has failed because of intolerance
Dasatinib 08.01.05 Formulary NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Dasatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Dasatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)
Degarelix 08.03.04.02 Formulary NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Non Formulary NICE TA265: Bone metastases from solid tumours - denosumab
Denosumab 06.06.02 Formulary NICE TA204: Osteoporotic fractures - denosumab
Denosumab 06.06.02 Formulary NICE TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema
Dimethyl fumarate 08.02.04 Formulary NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
Dipyridamole 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Docetaxel 08.01.05 Formulary NICE TA109: Breast cancer (early) - docetaxel
Docetaxel 08.01.05 Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Donepezil 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Doxorubicin Hydrochloride 08.01.02 Formulary NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)
Dronedarone 02.03.02 Formulary NICE TA197: Atrial fibrillation - dronedarone
Drotrecogin Alfa (Activated) 02.11 Formulary NICE TA84: Drotrecogin alfa (activated) for severe sepsis
Edoxaban 02.08.02 Formulary NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Edoxaban 02.08.02 Formulary NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Elbasvir/Grazoprevir 05.03.03.02 Formulary NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
Entecavir 05.03.03.01 Formulary NICE TA153: Hepatitis B (chronic) - entecavir
Entecavir 05.03.03.01 Formulary NICE CG165: Hepatitis B (incorporates TA153)
Enzalutamide 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Enzalutamide 08.03.04.02 Formulary NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
Eplerenone 02.02.03 Formulary NICE CG108: Chronic heart failure
Epoetin beta 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Eribulin 08.01.05 Formulary NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Eribulin 08.01.05 Formulary NICE TA250: Breast cancer (advanced) - eribulin
Erlotinib 08.01.05 Non Formulary NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib
Erlotinib 08.01.05 Non Formulary NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
Erlotinib 08.01.05 Non Formulary NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
Erlotinib 08.01.05 Formulary NICE TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Erlotinib 08.01.05 Formulary NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Erlotinib 08.01.05 Formulary NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Etanercept 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Etanercept 10.01.03 Formulary NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Etanercept 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Etanercept 13.05.03 Formulary NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept 13.05.03 Formulary NICE TA103: Psoriasis - efalizumab and etanercept
Everolimus 08.01.05 Formulary NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Everolimus 08.01.05 Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 08.01.05 Formulary NICE TA348: Everolimus for preventing organ rejection in liver transplantation
Everolimus 08.01.05 Non Formulary NICE TA295: Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor):
Everolimus 08.01.05 Non Formulary NICE TA219: Everolimus for second-line treatment of renal cell cancer
Evolocumab 02.12 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide prolonged release 06.01.02.03 Formulary NICE TA248: MR exenatide
Exenatide prolonged release 06.01.02.03 Formulary Nice Guidelines NG28: Type 2 diabetes in adults: management
Ezetimibe 02.12 Formulary NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Formulary NICE 164: Febuxostat for the management of hyperuricaemia in people with gout
Febuxostat 10.01.04 Non Formulary NICE TA164: Hyperuricaemia - febuxostat
Finasteride 06.04.02 Formulary NICE CG97: Lower urinary tract symptoms: quick reference guide
Fingolimod 08.02.04 Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fluocinolone acetonide intravitreal implant 11.04.01 Formulary NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271)
Fulvestrant 08.03.04.01 Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Galantamine 04.11 Formulary NICE TA 217: Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease
Gefitinib 08.01.05 Formulary NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gefitinib 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gemcitabine 08.01.03 Formulary NICE TA25: Pancreatic cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
Glatiramer Acetate 08.02.04 Formulary NICE TA32: Beta interferon and glatiramer acetate for the treatment of multiple sclerosis
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Golimumab 10.01.03 Formulary NICE TA220: Psoriatic arthritis - golimumab
Golimumab 10.01.03 Formulary NICE TA233: Ankylosing spondylitis - golimumab
Golimumab 10.01.03 Formulary NICE TA225: Rheumatoid arthritis - golimumab
Golimumab 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Harvoni 05.03.03.02 Formulary NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Ibrutinib 08.01.05 Formulary NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Idelalisib 08.01.05 Formulary NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
Imatinib 08.01.05 Formulary NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
Imatinib 08.01.05 Formulary NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA70: Leukaemia (chronic myeloid) - imatinib
Imatinib 08.01.05 Formulary NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Imatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
Imatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Infliximab 10.01.03 Formulary NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Infliximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Infliximab 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Infliximab 01.05.03 Formulary NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
Infliximab 13.05.03 Formulary NICE TA134: Infliximab for psoriasis
Insulin 06.01.01.01 Non Formulary Nice web site
Ipilimumab 08.01.05 Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ivabradine 02.06.03 Formulary NICE Guidelines GC126: Stable angina: management
Ivabradine 02.06.03 Formulary NICE TA267: Ivabradine for treating chronic heart failure
Ixekizumab 13.05.03 Formulary NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
Lapatinib 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Lenalidomide 08.02.04 Formulary NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenalidomide 08.02.04 Formulary NICE TA171: Multiple myeloma - lenalidomide
Liraglutide 06.01.02.03 Formulary NICE TA203: Diabetes (type 2) - liraglutide
Lubiprostone 01.06.07 Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Mannitol inhalation 03.07 Formulary NICE TA266 Cystic fibrosis - mannitol dry powder for inhalation (TA266)
Memantine 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Methylprednisolone 06.03.02 Formulary NICE CG8: Multiple Sclerosis; management in primary and secondary care.
Mifamurtide 08.02.04 Non Formulary NICE TA154: Hepatitis B - telbivudine
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Naftidrofuryl 02.06.04 Formulary NICE TA223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Naloxegol 01.06.06 Formulary NICE TA345: Naloxegol for treating opioid‑induced constipation
Naltrexone 04.10.03 Formulary NICE TA115: Drug misuse - naltrexone
Natalizumab 08.02.04 Restricted Use NICE TA127: Multiple sclerosis - natalizumab
Nilotinib 08.01.05 Formulary NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Nilotinib 08.01.05 Formulary NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Nilotinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nintedanib 08.01.05 Formulary NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Nivolumab 08.02.04 Formulary NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab 08.02.04 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.02.04 Formulary NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Ocriplasmin 11.08.02 Formulary NICE TA297: Ocriplasmin for treating vitreomacular traction
Ofatumumab 08.02.03 Formulary NICE TA202: Chronic lymphocytic leukaemia - ofatumumab
Ofatumumab 08.02.03 Formulary NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
Omalizumab 03.04.02 Non Formulary NICE TA278: Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201)
Ombitasvir/ paritaprevir/ritonavir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Oseltamivir 05.03.04 Formulary NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Osimertinib 08.01.05 Formulary NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Oxaliplatin 08.01.05 Non Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Paclitaxel 08.01.05 Non Formulary NICE TA108: Breast cancer (early) - paclitaxel
Paclitaxel 08.01.05 Non Formulary NICE TA55: Ovarian cancer - paclitaxel (review)
Paclitaxel 08.01.05 Formulary NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
Paclitaxel 08.01.05 Formulary NICE TA360: Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer
Pazopanib 08.01.05 Formulary NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
Pegaptanib Sodium 11.08.02 Non Formulary NICE TA155: guidance on pegaptanib in AMD (August 2008)
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa 08.02.04 Non Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pembrolizumab 08.01.05 Formulary NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA447: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pemetrexed 08.01.03 Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA309: Lung cancer (non small cell, non squamous) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Pemetrexed 08.01.03 Formulary NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pemetrexed 08.01.03 Formulary NICE TA124: Lung cancer (non-small-cell) - pemetrexed
Perampanel 04.08.01 Formulary NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pertuzumab 08.01.05 Formulary NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pimecrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
pirfenidone 03.11 Non Formulary NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone
Pixantrone 08.01.02 Formulary NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma
Pomalidomide 08.02.04 Formulary NICE TA338: Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib
Pomalidomide 08.02.04 Formulary NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 08.01.05 Formulary NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Formulary NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182)
Prucalopride 01.06.07 Formulary NICE TA211: Constipation (women) - prucalopride
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA160: quick reference guide on osteoporosis
Ranibizumab 11.08.02 Formulary NICE TA274: Ranibizumab for treating diabetic macular oedema
Ranibizumab 11.08.02 Formulary NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance
Ranibizumab 11.08.02 Formulary NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab
Ranibizumab 11.08.02 Formulary NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Ranolazine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina
Ribavirin 05.03.05 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.05 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Non Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Non Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Rifaximin 05.01.07 Formulary NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Formulary NICE TA20: Motor neurone disease - riluzole
Rituximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Rituximab 10.01.03 Formulary NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rituximab 08.02.03 Formulary NICE TA65: Non-Hodgkin’s lymphoma - rituximab
Rituximab 08.02.03 Formulary NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
Rituximab 08.02.03 Formulary NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
Rituximab 08.02.03 Formulary NICE TA137: Lymphoma (follicular non-Hodgkin's) - rituximab
Rituximab 08.02.03 Formulary NICE TA110: Follicular lymphoma - rituximab Non-Hodgkin's lymphoma - rituximab
Rituximab 08.02.03 Formulary NICE TA226: Lymphoma (follicular non-Hodgkin’s) - rituximab
Rituximab 08.02.03 Formulary NICE TA243: Follicular lymphoma - rituximab (review)
Rituximab 08.02.03 Formulary NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rivaroxaban 02.08.02 Formulary NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
Rivaroxaban 02.08.02 Formulary NICE TA287:Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban 02.08.02 Formulary NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivastigmine 04.11 Formulary NICE TA 217: Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease
Roflumilast 03.03.03 Formulary NICE TA244: Chronic obstructive pulmonary disease - roflumilast
Romiplostim 09.01.04 Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Ruxolitinib 08.01.05 Formulary NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril valsartan 02.05.05 Formulary NICE TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Secukinumab 13.05.03 Formulary NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 13.05.03 Formulary NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
Simeprevir 05.03.03.02 Formulary NICE TA331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
Sofosbuvir 05.03.03.02 Formulary NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir /Velpatasvir 05.03.03.02 Formulary NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
Somatropin 06.05.01 Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
Somatropin 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Sorafenib 08.01.05 Non Formulary NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
Sunitinib 08.01.05 Formulary NICE TA178: Renal cell carcinoma
Sunitinib 08.01.05 Formulary NICE TA169: Renal cell carcinoma - sunitinib
Sunitinib 08.01.05 Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Tacrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tadalafil 07.04.05 Formulary NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273)
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03.02 Formulary NICE TA252: Telaprevir for the treatment of genotype 1 chronic hepatitis C
Temozolomide 08.01.05 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Temozolomide 08.01.05 Non Formulary NICE TA23: Brain cancer - temozolomide
Temsirolimus 08.01.05 Formulary NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Temsirolimus 08.01.05 Formulary NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
Tenofovir Disproxil 05.03.01 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA173
Tenofovir Disproxil 05.03.01 Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Formulary NICE TA303: Teriflunomide for relapsing remitting MS
Thalidomide 08.02.04 Formulary NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Ticagrelor 02.09 Formulary NICE TA236: Ticagrelor for the treatment of acute coronary syndromes
Ticagrelor 02.09 Formulary NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tirofiban 02.09 Formulary NICE CG94: Unstable angina and NSTEMI: early management
Tirofiban 02.09 Formulary NICE TA47 : Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
Tobramycin inhaler 05.01.04 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Formulary NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab
Tocilizumab 10.01.03 Formulary NICE TA247: Rheumatoid arthritis - tocilizumab (rapid review TA198)
Tocilizumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tocilizumab 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tolvaptan 06.05.02 Formulary NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease
Topotecan 08.01.05 Non Formulary NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 08.01.05 Non Formulary NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)
Topotecan 08.01.05 Non Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Trabectedin 08.01.05 Non Formulary NICE TA222- ovarian cancer
Trabectedin 08.01.05 Non Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trametinib 08.01.05 Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trastuzumab 08.01.05 Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Formulary NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA107: Breast cancer (early) - trastuzumab
Trastuzumab emtansine 08.01.05 Formulary NICE TA371: Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane
Trifluridine-tipiracil 08.01.05 Formulary NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Ustekinumab 13.05.03 Formulary NICE TA180: Psoriasis - ustekinumab
Ustekinumab 13.05.03 Formulary NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 13.05.03 Formulary NICE TA: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Ustekinumab 13.05.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib 08.01.05 Formulary NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Zanamivir inhalation 05.03.04 Formulary NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Zolpidem 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Chelsea and Westminster Hospital